Kornimate/medical-research-clean huggingface dataset:
elastic band resistance exercise on glycated haemoglobin and muscle strength, balance, and physical function in patients with comorbid type 2 diabetes mellitus and knee osteoarthritis

Conditions: Elastic Band Resistance Exercise With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis

Summary: whether elastic band resistance exercise (ebre) as a home-based rehabilitation routine can control the glycated heamoglobin (hba1c) level and improve the muscle strength, dynamic balance, and physical function in older patients with comorbid t2dm and knee oa?

design: randomised controlled trial. participants: seventy patients diagnosed with t2dm together with knee oa. intervention: patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. the experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week. the control group underwent active joint range-of-motion exercises and isometric contraction exercises. the intervention regimens lasted 12 weeks.

Eligibility criteria:
inclusion criteria: * inclusion criteria for this study were as follows: age between 60 and 70 years; comorbid t2dm and knee oa diagnosed by a physician; and kellgren and lawrence (k\&l) grade \<3 based on the findings of plain radiographs. exclusion criteria: * exclusion criteria were as follows: inability to perform any self-activity; dm with complications, such as lower extremity neuropathy, retinopathy, stroke, foot wounds, or amputations; k\&l grade \>3, hip or knee arthroplasty; history of myocardial infarction; uncontrolled liver and kidney disease; and uncontrolled hypertension.

Keywords: home-based exercise, resistance band, cartilage degeneration, glycated haemoglobin control, diabetes mellitus
effect of tiotropium on airway remodeling in patients with early stage copd accessed by optical coherence tomography

Conditions: Airway Remodeling

Summary: the study aims to explore the effect of tiotropium on airway remodeling by using endobronchial optical coherence tomography (eb-oct). we enrolled patients with gold i stage copd. all the patients will be divided into four groups randomly to receive saba as needed with or without regular use of tiotropium. changes of airway morphology (accessed by eb-oct), pulmonary function, qol, and saba usage will be obtained.


Eligibility criteria:
key inclusion criteria * over 40 yrs; male or female diagnosed with copd * pre-bronchodilator fev1 ≥80% pred ; * patients must be able to perform all study related procedures exclusion criteria: * patients with other lung diseases (such as bronchiectasis, pneumothorax, pleural effusion, airway deformation, lung surgery, etc.). * patients have poor compliance and are unwilling to receive medication regularly. * other complications of bronchoscopy or intolerance of bronchoscopy procedure.
treatment and outcomes of atrial fibrillation and acute coronary syndrome in sweden

Conditions: Atrial Fibrillation

Summary: many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it. however, people with atrial fibrillation are also at increased risk of acute myocardial infarction or unstable angina pectoris (another heart condition marked by a chest pain, comprising so-called acute coronary syndrome for which another type of treatment that prevents blood from clotting (antiplatelet treatment) is indicated. in particularly if such patients undergo percutaneous coronary intervention, a procedure aimed to open up diseased blood vessels and hence to treat acute coronary syndrome, this treatment is needed. if a patients takes several anti-clotting blood drugs, the risk of bleeding is high. the number of possible drug combinations and treatment durations is large. this study will help us to understand which anti-clotting drug combinations are prescribed in real life among patients with atrial fibrillation and acute coronary syndrome, how effective and safe they are for patients. the study will look into the data that are already available in several very large swedish databases which contain information needed for the research.


Eligibility criteria:
inclusion criteria: * diagnosis of acs defined by a hospital discharge (icd-10 code of i21 for myocardial infarction or i20.0 for unstable angina pectoris (with or without sub-codes) during the study period and a diagnosis of af (icd-10 code i48 with or without sub-codes) in the patient register before or on the same day as the patient was discharged for acs. exclusion criteria: - no exclusions will be made as the registries capture the entire life-time of entire population of sweden.

Keywords: atrial fibrillation acute coronary syndrome anticoagulation
cliniccompanion. compared to the use of a goniometer

Conditions: Shoulder Impingement Syndrome

Summary: in this study, the goal is to find out if the cliniccompanion™ is effective in measuring range of motion when compared to the goniometer. currently, the goniometer is an approved device to measure range of motion by the fda, but the cliniccompanion™ is not.

the study procedure will test the range of motion of the subjects shoulders two different ways: using a goniometer and using the cliniccompanion™. both tools are designed to measure the degree of movement subjects are able to do. researchers will take 12 measurements on each arm for each device, for a total of 24 measurements per device. that is a total of 48 measurements for both devices.

Eligibility criteria:
inclusion criteria: * new or established clinic patients from pi's medical practice at aurora st. luke's medical center * 18 years of age and older exclusion criteria: * no use of limbs * amputees

Keywords: rotation shoulder joint rom abduction, internal rotation, external rotation, flexion normal joint movement physical examination
buprenorphine's dose response curve

Conditions: Opioid-related Disorders

Summary: this is a residential study that looks at the effects of buprenorphine in persons who abuse but are not dependent on opioids. animal studies show that very high doses of buprenorphine produce less effects than mid-range doses. this suggests that buprenorphine can be a very safe medication. however, no studies in humans have tested higher doses in a similar way. the goal of this study is to show the effects of single doses of buprenorphine, across a range of doses, in persons who are not physically dependent on opioids (but do abuse opioids).

preclinical studies have demonstrated for a variety of measures that buprenorphine has a bell-shaped dose response curve. however, human studies with buprenorphine have not shown such an effect, although controlled studies have generally not tested higher acute doses of buprenorphine. current clinical recommendations generally place an upper limit of daily buprenorphine dosing at 32 mg of sublingual tablets, although considerably higher acute doses have been administered to humans (primarily in clinical studies of less than daily dosing). determining the relationship between higher doses of buprenorphine in humans and effects produced would be valuable; it would be scientifically interesting to demonstrate a bell-shaped curve in humans, and it would help guide clinical practice (for example, with respect to dosing, safety, and side effect considerations. the purpose of this study is to characterize the dose response curve for buprenorphine in humans, utilizing acute single doses of parenteral buprenorphine.

Eligibility criteria:
inclusion criteria: 1. current opioid abuse but not physically dependent on opioids exclusion criteria: 1. evidence of significant medical (e.g., insulin dependent diabetes) or psychiatric (e.g., schizophrenia) illness 2. anemia defined as a hematocrit less than 30% 3. females are required to provide a negative pregnancy test prior to study participation 4. baseline electrocardiogram (ecg) showing prolongation of the corrected qt interval (qtc) 5. current significant alcohol or sedative/hypnotic drug use 6. forced expiratory volume at one second (fev1) of less than 50% at the time of screening 7. applicants seeking treatment for their substance abuse will not be admitted to the study, and should be provided information about treatment services available

Keywords: opioid addiction opioid dependence buprenorphine
electroencephalography based neurofeedback in chronic neuropathic pain

Conditions: Neuropathic Pain

Summary: chronic neuropathic pain is a global health concern, affecting millions of patients worldwide. it is often extremely debilitating and poses a diagnostic and therapeutic challenge. the current mainstay of treatment is pharmacotherapy consisting of powerful analgesics combined with different classes of drugs that change nerve cell membrane properties. however, response to pharmacotherapy is often poor and mandates interventional strategies. among the latest and most promising interventional strategies is the use of neurostimulation to targeted brain areas, specifically the primary motor cortex . motor cortex stimulation , both invasive and noninvasive (using megnetic or electical stimulation), has emerged as a highly beneficial treatment, and is currently included in different professional guidelines for the treatment of medically refractory neuropathic pain. a possible alternative way to achieve stimulation of the motor cortex is by using eeg based neurofeedback. this design, which is actually a brain computer interface (bci) enables the patient to voluntarily modulate the activity of a circumscribed brain area after a few training sessions. while eeg based neurofeedfback is decades old, it has never been tested in neuropathic pain patients. this experiment is intended to compare both the clinical effects and the brain correlates of a bci based self modulation of m1 activity and of exogenous magnetic brain stimulation in a population of patients suffering from chronic neuropathic pain of an upper limb. 15 such patients will receive a course of 10 daily magnetic stimulation sessions with stimulation of m1 as described in the literature. a further 30 patients will be divided into two groups: 15 will perform a course of 10 real bci neurofeedback sessions modulating motor cortex activity and 15 will perform a course of 10 sham neurofeedback sessions. the participants' baseline chronic pain levels and their response to acute painful stimuli will be clinically evaluated before and after the course, and for an additional 1 month. furthermore, before and after the course patients will be scanned using functional mri during rest (baseline pain levels) and during acute pain. these scans are performed both to describe the neural correlates of the analgesia induced by motor cortex magnetic stimulation , and to compare the observed networks to the network effect of a bci neurofeedback modulation of motor cortex activity.


Eligibility criteria:
inclusion criteria: * 18-65 years old, treated medically for neuropathic pain of an upper arm with unsatisfactory results (average daily vas score over 4) exclusion criteria: * cognitive decline, * malignant disease, * focal neurological deficit, * illegal substance abuse * noncompliance with medical therapy or follow up.

Keywords: neuropathic pain neurostimulation
questionnaire survey of the advanced training program for laparoscopic radical gastrectomy

Conditions: Gastric Cancer

Summary: this study aims to evaluate the outcomes of the advanced training program for laparoscopic radical gastrectomy (atp-lrg). the research subjects are the trainees who participated in this training program.

written informed consent is not required because of the observational and anonymous nature of this study. atp-lrg is a national training program carried out by fujian medical university union hospital. each training lasts about 1.5 days, which includes 1) detailed technique description; 2) prevention and solving of intraoperative complications; 3) live surgery performance; 4) theory and practice of clinical research; 5) comments on trainees' videos; and 6) questions, answers and discussions. in this study, 875 trainees who participated in atp-lrg from january 2015 to october 2020 were interviewed using electronic questionnaires. using a repeated-measures design to examine differences in outcomes before and after participating in the training. questionnaire star (changsha ranxing information technology co., ltd), a most widely used professional online questionnaire software platform in china, was used to design and create a link to the questionnaire. the questionnaire's link was sent to each trainee via wechat (tencent holdings limited), the most commonly used social networking software in china.

Eligibility criteria:
inclusion criteria: * participated in atp-lrg between january 2015 and october 2020 * have contact information exclusion criteria: * repeated participation in atp-lrg * refuse to fill out the questionnaire
assessment the diagnostic value of pro-neurotensin as a serum biomarker in masld

Conditions: Steatosis of Liver

Summary: to assess the diagnostic significance of serum pro-nt in masld and ability to differentiate between early and advanced steatosis.


Eligibility criteria:
inclusion criteria: * asymptomatic adults were randomly recruited from relatives of patients in tropical medicine and gastroenterology outpatient clinic or the inpatient section of the department. participants were categorized as masld patients if their abdominal us examination showed the criteria of fatty liver as described later or non-masld (controls) if they did not show these criteria. exclusion criteria: * (i) patients aged \ 75 years. (ii) history of alcohol consumption. (iii) a diagnosis of liver diseases other than masld, including viral hepatitis, drug-induced liver injury, clinically suspected cases of autoimmune liver disease, wilson's diseases, primary biliary cholangitis. the control group had no illness to cause any inflammation; no usage of alcohol, drug, or herbal substances; no history of previous liver diseases; and was negative for viral hepatitis serology tests and had completely normal liver us.
diffuse diabetic maculopathy with intravitreal triamcinolone or laser

Conditions: Macular Edema

Summary: this study compares the use of intravitreous triamcinolone and laser therapy to treat maculopahty in patients with type 2 diabetes mellitus in a short-tem period of 6 months

the purpose of this double blind randomized clinical trial was to compare the treatment of diffuse diabetic macular oedema with intravitreal triamcinolone and laser in patients with type 2 diabetes mellitus (dm), using a morphofunctional assessment. patients with clinically significant diffuse macular oedema, previously untreated and with a macular thickness \>250 μm at optical coherence tomography (oct) were randomized for treatment with laser or intravitreal injection of triamcinolone acetate. optical coherence tomography (oct), biomicroscopy, fundoscopy, fluorescein angiography, tonometry, scotometry, visual acuity and contrast acuities were performed at 0, 1, 3 and 6 months.

Eligibility criteria:
inclusion criteria: * patients with type 2 dm, diffuse macular oedema secondary to diabetic retinopathy, seen at the centre of reference for diabetic retinopathy at hospital de clinicas de porto alegre (hcpa) and at the ophthalmology outpatient clinic at hcpa, exclusion criteria: * patients with type 2 dm and previous treatment of diffuse macular oedema secondary to diabetic retinopathy

Keywords: diffuse macular oedema type 2 diabetes mellitus laser therapy
a study to evaluate the safety, pharmacokinetics, and efficacy of topical esr-114 in subjects with plaque psoriasis

Conditions: Psoriatic Plaque

Summary: this is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied esr-114 following twice daily (bid) application for 42 days (6 weeks).


Eligibility criteria:
inclusion criteria: * subject has a history of plaque psoriasis for at least 6 months. * subject has pga of mild (2) or moderate (3) at day 1. * subject has total lss of ≥6 at day 1. * subjects with plaque psoriasis-affected bsa to be treated of 1% to 15% at screening and day 1. exclusion criteria: * subject has non-plaque psoriasis at screening and day 1. * subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments at screening and day 1. * subject has used any topical therapy to treat psoriasis within 2 weeks prior to day 1.
curosurf and survanta treatment(cast)of rds in very premature infants

Conditions: Prematurity; Respiratory Distress Syndrome; Patent Ductus Arteriosus

Summary: approval of surfactant by the fda in 1989 for the treatment of respiratory distress syndrome (rds) in premature infants greatly improved survival rates. newer surfactants approved by the fda were more concentrated and had a more rapid onset of action. the overall efficacy of newer surfactants appeared similar until in 2004, ramanathan and colleagues suggested that a double dose of curosurf improved survival in infants 25-32 weeks gestational age, compared to infants treated with survanta, the most commonly used surfactant preparation in the united states. while the data was suggestive, it was not clear that the improvement in survival was reproducible or that curosurf was responsible for the improved survival rates. the purpose of this study was to investigate the role of curosurf in improving lung function and survival rates and reducing the complications of prematurity in very premature infants \< 30 weeks gestational age at birth.

specific aims: * to determine whether there is a sustained difference in the level of respiratory support during the first 3 days of life in extremely premature infants treated with curosurf versus survanta * to determine whether curosurf is associated with a higher incidence of hemodynamically significant pda, compared with survanta * to determine whether there is a difference in the cerebral blood flow response to curosurf versus survanta * to determine whether there is a difference in morbidity in very premature infants treated with curosurf versus survanta we reasoned that if curosurf was primarily responsible for improved survival rates, compared with survanta, then there should be a sustained improvement in respiratory function in the first three days of life, when the direct pulmonary effects of the surfactant preparations would be most easily detected. it was also possible that curosurf and survanta could have effects on other systems that could secondarily affect long-term survival of the infant. these other organ systems would include, but not be limited to, the development of a hemodynamically significant patent ductus arteriosus, intraventricular hemorrhage or periventricular leukomalacia, or necrotizing enterocolitis. we propose to examine how surfactant administration affected the hemodynamic precursors of these common morbidities of very premature infants.

Eligibility criteria:
inclusion criteria: * \ 24 0/7 weeks gestational age * inborn at the participating institution enrolling the patient * fio2 \>25% and intubated with mean airway pressure \> 5 cm h20 * \<8 hours age at randomization * signed informed consent from parent(s) exclusion criteria: * \<500 g birth weight * \<24 0/7 weeks gestational age (best estimate) * prolonged premature rupture of membranes \>3 weeks (21 days) * apgar score \< 3 at 5 minutes * impending death anticipated within the first 3 days of life, moribund * severe congenital anomalies

Keywords: very premature rds surfactant
efficacy and safety of near infrared light therapy for alzheimer's disease

Conditions: Mild to Moderate Alzheimer's Disease

Summary: to explore the efficacy and safety of near infrared light therapy for alzheimer's disease. each subject will be numbered and their medical records will be established. the subjects will be randomly assigned to the treatment group or the control group for 30 minutes/day (5-6 days a week) for 4 months while the treatment group is active settings and the control group is sham settings.follow-up visits will be conducted at 2 months, 4 months and 2 months after treatment. at each follow-up, scale assessment, blood, mri, and eeg were observed


Eligibility criteria:
inclusion criteria: * the age of registration is 50-85 years old, male or female. * the mmse score \< 26 points can be used to complete the scale assessment. * patients who are not on medication and who are taking psychotropic or cognitive-improving drugs must have a stable dose for at least 12 weeks before the trial and remain the same for the duration of treatment. * agree to participate in the clinical trial, willing to maintain the original treatment plan during the trial, and have signed the informed consent exclusion criteria: * mri showed evidence of abnormalities other than alzheimer's disease, such as cerebral infarction at key sites and severe leukodystrophy (fezakas\>level 3). * there are contraindications to mri scanning, such as metal implants, claustrophobia, etc. * a history of stroke or seizures. * photosensitive to sunlight or visible light, eczema or increased sensitivity of the skin at the treatment site. * severe vision or hearing impairment. * alcohol dependence, drug or other drug addiction or addiction tendency. * during the study , subjects were pregnant, breastfeeding, or planning to pregnancy. * he/she is currently participating in another study related to the treatment of ad. * researchers think that participants could not be included.
evaluation of the containment impact linked to the covid-19 pandemic in a population of parkinson patients

Conditions: Parkinson Disease; COVID

Summary: the consequences of covid-19 in these already fragile patients should be evaluated. it will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. these consequences can be assessed by the end of confinement and 6 months after the latter is lifted.

adaptation capacities are necessary to cope with the brutal and drastic changes imposed by the pandemic and its consequences. in parkinson's disease, where there are routine situations with difficulties adjusting to newness, patients in the current situation may be particularly affected and present anxiety due to great difficulties in adaptation. the repercussions in terms of symptoms (motor and non-motor) of the disease could be very significant. in this population already widely exposed to anxio-depressive symptoms (depression being a common symptom of parkinson's disease, affecting up to 30 to 40% of patients outside of crisis periods), we can expect a risk increased psychiatric decompensation. the psychiatric consequences could not be limited to the current period but also concern long-term patients, in particular if there is decompensation of other symptoms of the disease (motors, complications linked to treatment, etc.). the consequences of covid-19 in these already fragile patients should be evaluated. it will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. these consequences can be assessed by the end of confinement and 6 months after the latter is lifted. this is an observational, french multicenter study, of an uncontrolled cohort of parkinsonian patients followed by doctors from parkinson expert centers in hospitals.

Eligibility criteria:
inclusion criteria: * patient followed by a doctor from the parkinson expert center of the toulouse university hospital, lille, paris, rouen, nimes, reims, besancon, marseille * and with idiopathic parkinson's disease * patients hospitalized or in consultation between 16/03/2020 and 16/05/2020. exclusion criteria: * atypical parkinsonian syndrome * patient subject to a legal protection order (tutorship) * patient not wishing to answer questions

Keywords: parkinson disease, covid-19 confinement